Your browser doesn't support javascript.
loading
The Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies.
Raeder, Vanessa; Batzu, Lucia; Untucht, Robert; Fehre, Annekathrin; Rizos, Alexandra; Leta, Valentina; Schmelz, Renate; Hampe, Jochen; Bostantjopoulou, Sevasti; Katsarou, Zoe; Storch, Alexander; Reichmann, Heinz; Falkenburger, Björn; Ray Chaudhuri, K; Klingelhoefer, Lisa.
Afiliação
  • Raeder V; Department of Neurology, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany.
  • Batzu L; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.
  • Untucht R; Department of Basic and Clinical Neuroscience, King's College London, Institute of Psychiatry, Psychology, and Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, London, United Kingdom.
  • Fehre A; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu, Berlin, Germany.
  • Rizos A; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.
  • Leta V; Department of Basic and Clinical Neuroscience, King's College London, Institute of Psychiatry, Psychology, and Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, London, United Kingdom.
  • Schmelz R; Department of Neurology, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany.
  • Hampe J; Department of Neurology, Elblandklinikum Meißen, Meißen, Germany.
  • Bostantjopoulou S; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.
  • Katsarou Z; Department of Basic and Clinical Neuroscience, King's College London, Institute of Psychiatry, Psychology, and Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, London, United Kingdom.
  • Storch A; Parkinson's Foundation Centre of Excellence, King's College Hospital, London, United Kingdom.
  • Reichmann H; Department of Basic and Clinical Neuroscience, King's College London, Institute of Psychiatry, Psychology, and Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, London, United Kingdom.
  • Falkenburger B; Department of Internal Medicine I, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany.
  • Ray Chaudhuri K; Department of Internal Medicine I, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany.
  • Klingelhoefer L; 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Front Neurol ; 14: 1149604, 2023.
Article em En | MEDLINE | ID: mdl-37056364
Objective: A total of 48% of patients with Parkinson's disease (PD) present symptoms of gastrointestinal dysfunction, particularly constipation. Furthermore, gastrointestinal tract (GIT)-related non-motor symptoms (NMSs) appear at all stages of PD, can be prodromal by many years and have a relevant impact on the quality of life. There is a lack of GIT-focused validated tools specific to PD to assess their occurrence, progress, and response to treatment. The aim of this study was to develop and evaluate a novel, disease- and symptom-specific, self-completed questionnaire, titled Gut Dysmotility Questionnaire (GDQ), for screening and monitoring gastrointestinal dysmotility of the lower GIT in patients with PD. Methods: In phase 1, a systematic literature review and multidisciplinary expert discussions were conducted. In phase 2, cognitive pretest studies comprising standard pretests, interviews, and evaluation questionnaires were performed in patients with PD (n = 21), age- and sex-matched healthy controls (HC) (n = 30), and neurologists (n = 11). Incorporating these results, a second round of cognitive pretests was performed investigating further patients with PD (n = 10), age- and sex-matched HC (n = 10), and neurologists (n = 5). The questionnaire was adapted resulting in the final GDQ, which underwent cross-cultural adaptation to the English language. Results: We report significantly higher GDQ total scores and higher scores in five out of eight domains indicating a higher prevalence of gastrointestinal dysmotility in patients with PD than in HC (p < 0.05). Cognitive pretesting improved the preliminary GDQ so that the final GDQ was rated as relevant (100/100%), comprehensive (100/90%), easy to understand concerning questions and answer options (100/90%), and of appropriate length (80/100%) by neurologists and patients with PD, respectively. The GDQ demonstrated excellent internal consistency (Cronbach's alpha value of 0.94). Evidence for good construct validity is given by moderate to high correlations of the GDQ total score and its domains by intercorrelations (r s = 0.67-0.91; p < 0.001) and with validated general NMS measures as well as with specific items that assess gastrointestinal symptoms. Interpretation: The GDQ is a novel, easy, and quick 18-item self-assessment questionnaire to screen for and monitor gastrointestinal dysmotility with a focus on constipation in patients with PD. It has shown high acceptance and efficacy as well as good construct validity in cognitive pretests.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article